All News

Funding will support further development of recently acquired small molecule assets for treatment of autoimmune disease.

PAA showcases its complete range of automation solutions, suitable for any type of laboratory or application, at SLAS2018.

Company also promoted to Platinum supplier status in Europe.

A new analytical tool, Electrical Asymmetrical Flow Field-Flow Fractionation (EAF4) is showing much promise in biopharmaceutical and nanoparticle applications.

Fexinidazole would be first all-oral treatment under investigation for both first and second stages of sleeping sickness, a fatal disease, endemic in Africa.

Pall Biotech to focus on enabling drug manufacturers to rapidly transition from pre-clinical to commercial manufacturing.

Love it or loathe it, plastic is here to stay, but that doesn't let the pharmaceutical industry off the hook.

The expansion at Charles City is in parallel to the investments announced in 2017 at Cambrex’s facility in High Point, North Carolina.

Strengthens Sanofi's R&D strategy with innovative Nanobody technology platform.

Forté Pharma's new nutritional supplement combines natural extracts: valerian, passionflower, and vitamins B3 and B6, which contribute to prolong sleep for 8 hours.

The companies have 15 days to respond to the FDA and FTC.

Enamine REAL database of synthetic compounds accessible via UCSF’s online ZINC platform.

Commercial manufacturing of Cinryze drug product in Vienna to begin in the first quarter of 2018.

LifeArc and Milner Therapeutics Institute to develop, validate and integrate cutting-edge machine learning approaches into drug discovery processes.

Sanofi to acquire Bioverativ for $11.6 billion.

Collaboration will leverage combined strengths of development, manufacturing and commercialization of biosimilars.

KWS increases Charles River's ability to support clients’ early-stage drug research in critical therapeutic areas.

Cobra Biologics (Cobra) announced that it has been awarded £2.6 million ($3.4 million) capital infrastructure investment by Innovate UK. The award has been made under Innovate UK’s Industrial Strategy boost for UK medicines with £70 million of funding ...

Craigavon, N.I., 18 January 2018 – Almac Group, the global contract pharmaceutical development and manufacturing organisation, today confirmed the successful completion of Health Products Regulatory Authority (HPRA) inspections of Almac Clinical Servic...

With time running out, Meditraq launches to simplify serialisation data challenge.

Through the acquisition of Nautilus Biosciences, Croda will utilise the company's innovative science for applications across all its market sectors.

Opening ceremony marks long-term supply agreement between Cambrex and AstraZeneca for a key intermediate.

New Year CPHI Japan report predicts 2018 will be a transformative year for Japanese pharma, with early movers likely to benefit.

A summary and highlights of new drug therapy approvals and other drug therapy advances in 2017 by FDA's CDER.

Three anti-ageing and anti-stress active ingredients for manufacturers of skin care product

The MedStat-HT and MedFlux-HT help to de-risk development programs and shorten development timelines.

The new formulation is proven to reduce blood sugar levels and may have the added benefit of weight loss.

New 3D technology provides a powerful platform for skin care researchers wishing to study the function of sebaceous glands, in relation to a range of age-related, microbial and inflammatory skin disorders.

Health investors are paying attention to Canada, particularly to Toronto’s hot market.

Acquisition will expand Takeda’s late-stage pipeline and leadership in gastroenterology.

"The precision and flexibility of zinc finger proteins enables targeting of virtually any genetic mutation."

Data supporting designation showed over half of treatment-naïve SAA patients achieved complete response with Promacta when given with standard immunosuppressive therapy, with overall response rate of 85%.

SSB will provide both facilities with end-to-end process solutions in single-use format.

Targeting the initiation of a pivotal patient clinical trial in the first half of 2018.

Ideal for a wide variety of pharmaceutical applications.

Designation based on Phase III MONALEESA-7 results demonstrating superior efficacy of Kisqali in combination with oral endocrine therapy compared to oral endocrine therapy in pre- or perimenopausal women who received no prior endocrine therapy for adva...

SRK-015 to move into clinical development for Spinal Muscular Atrophy (SMA) in first half of 2018; development in additional neuromuscular disorders to follow.

The transaction will allow Recipharm to combine and better exploit operational synergies with the company's other Indian business.

Martyn Davies recognised for his contribution to UK science and his ground-breaking achievements in pharmaceutical research and drug development.

Company envisions the development and IND filings of multiple “next-frontier” CAR-T programs in 2018 and beyond, which will position the company as a potential major player in the fast-growing CAR-T space of immunotherapies against cancers.

If approved, Tafinlar + Mekinist expected to be the first adjuvant targeted therapy combination to demonstrate a significant clinical benefit in patients with a BRAF V600 mutation.

Libbs will commercialize the product in Brazil under the brand name Zedora.

Mylan now offers estradiol in four delivery methods.

The additional capacity from this site is a key element to support the growth in the company's Immunology franchise.

The PDUFA goal date for completion of the FDA review of the Epidiolex NDA is 27 June 2018.

The exclusive launch of Teva's generic version of Reyataz marks the company's fifth generic product offering for the treatment of HIV-1 infection.

First and only CML therapy with Treatment-free Remission data in its label.

Sanofi and Alnylam's patisiran MAA to be reviewed under accelerated assessment.

Clinical studies showed 95% symptom improvement at one minute and reduced redness for up t 8 hours.

iMatrix recombinant Laminin-511 E8 protein fragments permit ES/iPS cells to be maintained in xeno-free, feeder-free culture conditions enabling easy application in medical trials.

Allergan plans to file petitions for rehearing of the appeals court decision and has asserted a new Orange Book patent against Sandoz's generic version of Combigan.

Health Canada requests additional technical information on Gynoflor to complete its assessment of the product.

Human polyclonal antibodies show promise as effective treatment.

Merger integrates Crown Bioscience’s leading translational technology platform providing drug target validation, efficacy testing and patient response characterization with JSR’s IVD solutions, GMP manufacturing capabilities and worldwide distribution ...

New collaboration agreement to identify new antisense oligonucleotide drug candidates.

First and only FDA-cleared PK dosing software to support healthcare professionals in creating personalized dosing regimens for patients 16 and older with hemophilia A.

Project will innovate technologies in epigenetic characterisation for patient stratification in renowned precision medicine.

Researchers find target to protect hearing during chemotherapy treatment.

Bora Pharmaceuticals to pay purchase price of $18.5 million and will have the rights to market and sell Impax's branded Parkinson's drug Rytary (Numient outside the US) in Taiwan.

Integration of supply chain a critical issue as industry globalises, with a resurgence in European manufacturing and biotech markets forecast.

Truxima is mAb biosimilar to Roche's MabThera (rituximab).

Collaboration to conduct clinical trials of the combination treatment in both cervical and head-and-neck cancer.

Total cost base to be reduced by $3 billion by the end of 2019.

Targeted formulas support symptoms before, during and after menopause.

Companies will strive to make diabetes management easier through effective use of connected devices and a diabetes management software platform.

Drug trials provide mind-blowing results.

Freeze-dried, or lyophilized, formulation aims to improve supply management by providing the same dosing regimen as liquid Oncaspar but with a three-times longer shelf life of up to 24 months.

First clinical candidate, HPN424, is in development for the treatment of metastatic prostate cancer and expected to enter Phase I clinical trials in 2018.

Service complements existing services for this testing, to provide comprehensive analysis and characterization solutions for clients involved in the production and manufacturing of biopharmaceutical products.

New version of SIMCA -advanced data analytics and visualization program - unlocks the hidden gems that hold the secret to better decision-making and greater business success.

Investment builds on company's expertise in small molecule analysis and the use of LC/MS-MS techniques.

What did you miss? Read an expert analysis of top, need-to-know information presented at this year’s CPHI Worldwide Pre-Connect Congress.

The development will help meet growing global demand for albumin.

The design, planning and building work commences immediately and will deliver a purpose-built, dual-stream facility.

Public and private investors look set to remain supportive of innovative, early-stage drug developers.

A highly automated system to speed up testing, improve reproducibility, and enhance data output and recording.

IDMC concludes that the study is unlikely to meet its primary objective.

Since the MAH pilot launch, the company has undertaken eight development programs.

Company executing long-term strategy to develop broad manufacturing capabilities for both vector supply and drug product supply to support clinical development and commercialization across pipeline.

Study provides further evidence that it is possible to reduce the burden of long-term inhaled steroids in many COPD patients.

CPHI and Clarivate Analytics have joined forces to bring you a new report on manufacturing and distribution practices, generics trends, biosimilars strategy, business development and more.

MSD's announcement to establish UK Discovery Centre in London an 'endorsement' of the government's Industry Strategy.

Recipharm's four French facilities now serve over 50 of its customers worldwide, including a number of top 20 pharma firms.

CDMO's serialisation capabilities in place ahead of US deadline to avoid potential problems for our customers.

The Stax mAx, a single-use harvesting platform, minimizes the impact of process variability between batches.

Offers customers a comprehensive, risk-based approach to the monitoring of data quality throughout the course of a study.

Amgen launches the Enbrel Mini single-dose prefilled cartridge with AutoTouch reusable autoinjector, which is ergonomically designed for patients.

We believe that science is the key to success. Although vitamin MK-7 assay tests can cost up to 1,000 Euro per test, Kappa is making this investment to help ensure the healthy development of the vitamin K2 market. 
Testing ensures that consum...

The acquisition will facilitate the growth of Shanghai Pharma's pharmaceutical manufacturing business.

Unique training courses designed around real-life situations, with hands-on access to enabling technologies.

Germany tops quality-ranking categories in the inaugural CPHI Global Pharma Index.

Quotient Sciences Translational Pharmaceutics platform integrates formulation development, real-time adaptive GMP manufacturing and clinical research.

New ARB technology rejuvenates existing antibiotics to outsmart antibiotic resistance.

Perception of India’s API manufacturing seems to be improving.

Experts at ADC Bio warn of impending problems in the ADC pipeline with millions wasted in development costs.

The upgraded BRS simulators make it even easier to apply specified inhalation profiles during OIP testing.

Controlled-release technologies will continue to be focal point, whereas techniques to improve solubility are likely to gain popularity.

The pharmaceutical service provider will be better positioned to support local and global customers, helping them to meet stringent development, manufacturing and packaging requirements of their injectable drugs.

Company's decision affects approximately 225 staff, specialised in tablet manufacturing, and in sachet and stick pack filling, primarily for powders and granules.

Two 500-gallon glass-lined reactors installed to reduce potential bottlenecks.

India Signing Hands provides premium quality communication services to carry on any business for the Deaf using Indian Sign Language (ISL). 
All the services of India Signing Hands are dedicated to the improvement of accessibilit...

The process, which uses significantly less materials than the manual alternatives, will ultimately improve drug developers’ clinical pathway.

The launch of avelumab marks a step-change in the way that mMCC can be treated.

For the first time for any biologic, data show almost 80% of ankylosing spondylitis patients on Cosentyx have no radiographic progression of the spine at 4 years.

Financing to advance its pipeline of neoantigen cancer-based immunotherapies to the clinic.

Zelboraf is the first FDA-approved treatment for Erdheim-Chester disease ECD, a rare blood disease.

Economic and political turmoil along with inefficient patent laws and drug pricing policies are major barriers.

Post-hoc analysis shows pain improvement was consistent regardless of a patient's baseline pain severity.

Combined technology assets will provides pharmaceutical and biotech customers the unique opportunity to select a tailored expression system.

Bio-Kult Infantis receives Best Mother and Baby Care Product Award in the Natural Pharmacy Business Awards 2017!

Natural Pharmacy Business is the UK’s leading natural pharmacy trade magazine, dedicated to growing pharmacists' knowledge of natu...

Rizaport is a proprietary oral thin-film formulation of rizatriptan for the treatment of acute migraines.

Company says it has found "no evidence of price fixing on the part of Mylan or its employees".

Acquisition would add Lutathera, a first-in-class RadioLigand Therapy approved in Europe and under review in the US for neuroendocrine tumours.

This nanomedicine candidate is specifically designed to enable enhanced tumour accumulation and local drug release at the target site, to boost the therapeutic efficacy and to overcome the shortfalls associated with current docetaxel products.

TraceLink selected for its demonstrated EU and country compliance capabilities and enterprise scalability.

Forté Pharma expands its energy and health segments with the launch of eight references in the French market, as a result of its product development strategy.

Craigavon, N.I., 01 November 2017 - Almac Group, the global contract development and manufacturing organisation, today announced the acquisition of 100% shares of BioClin Laboratories, an independent and privately owned organisation based in Athlone,...

Accelerated approval of Bruton tyrosine kinase inhibitor in MCL marks AstraZeneca's entry into the treatment of blood cancers.

Company now boasts having the highest quality standards from both its in-house manufacturing and its external partners, who are also audited and certified.